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The adrenal gland comprises two endocrine tissues of distinct
origin, the catecholamine-producing medulla and the steroid-
producing cortex. The inner adrenocortical zone, which is in direct
contact with the adrenomedullary chromaffin cells, produces de-
hydroepiandrostendione (DHEA) and DHEA sulfate (DHEAS). These
two androgens exhibit potential effects on neurogenesis, neuronal
survival, and neuronal stem cell proliferation. Unlike the closely
related sympathetic neurons, chromaffin cells are able to prolifer-
ate throughout life. The aim of this study was to investigate the
effect of DHEA and DHEAS on proliferation of bovine chromaffin
cells from young and adult animals. We demonstrated that graded
concentrations of leukemia inhibitory factor induced proliferation
of chromaffin cells from young animals, whereas EGF had no effect.
On the contrary, EGF increased the cell proliferation in cells from
adult animals, whereas leukemia inhibitory factor was inactive. In
both cases, DHEA decreased the proliferative effect induced by the
growth factors. Surprisingly, DHEAS enhanced, in a dose-depen-
dent-manner, the effect of growth factors on proliferation in cells
from adult animals but not from young animals. Flutamide, ICI
182,780, and RU 486 had no effect on the action of DHEA or DHEAS
on chromaffin cell proliferation. These data show that DHEA and
its sulfated form, DHEAS, differentially regulate growth-factor-
induced proliferation of bovine chromaffin cells. In addition, the
sensitivity of chromaffin cells to different growth factors is age-
dependent. Furthermore, these two androgens may act through a
receptor other than the classical steroid receptors.
aging  adrenal medulla  neurosteroid  paracrine interactions
The mammalian adrenal gland consists of two anatomicallydistinct parts derived from different embryological origins.
The outer cortex, which synthesizes steroid hormones, and the
central medulla, which contains catecholamine-producing chro-
maffin cells, are functionally and structurally closely connected
(1–3). Axelrod and Wurtman’s groups have demonstrated the
key role of adrenal glucocorticoids on the induction of catechol-
amine enzymes in chromaffin cells (4, 5). However, little is
known about the role of dehydroepiandrostendione (DHEA)
and DHEA sulfate (DHEAS) on chromaffin cell function. In
particular, DHEA-producing adrenal cortical cells are tightly
intermingled with adrenomedullary cells, providing ample con-
tact surface for paracrine interaction (Fig. 1). DHEA and
DHEAS, the most abundant steroids in the human body, have
been shown to play a neuroprotective role against excitatory
amino acid-induced neurotoxicity (6) while increasing neuro-
genesis (7) in the adult rodent hippocampus in vivo. Together
with the age-dependent decline of DHEA levels, there is a
decline in adrenomedullary function over life. In addition, it has
previously been shown that anti-androgen treatment may cause
cardiovascular effects by altering catecholamine biosynthesis
pathways in the adrenal medulla (8). Hyperandrogenism as seen
in patients with 21-hydroxylase deficiency is associated with
structural and functional alterations of the adrenal medulla (9,
10). Furthermore, recent evidence suggests an antiapoptotic
effect of DHEA and DHEAS on chromaffin cells (11) and
opposite effects of these two androgens on catecholamine se-
cretion (12, 13).
Interestingly, chromaffin cells, in contrast to closely related
sympathetic neurons, are able to proliferate throughout life (14).
Proliferation of chromaffin cells constantly requires the presence
of growth factors, including nerve growth factor, insulin-like
growth factor II, and fibroblast growth factor type II (14). EGF
is expressed by the adrenal cortex, and EGF binding sites have
been found on chromaffin cells (15) suggesting that EGF acts as
a paracrine factor in the adrenal gland. There is now plentiful
evidence that EGF enhances cell proliferation in PC12 cells, a
cell line established from a rat pheochromocytoma (16); how-
ever, little is known about the action of EGF on normal
chromaffin cells. Leukemia inhibitory factor (LIF) is a pleiotro-
pic cytokine that belongs to the IL-6 family. LIF is released by
various types of immune cells (17) and adrenocortical cells (18).
This cytokine is known to be strongly involved in the develop-
ment and maintenance of hypothalamic–pituitary–adrenal axis
(18–20) as well as sympathetic neurons and adrenal medullary
development (21). To explore the role of adrenal androgens on
adrenal development, we investigated the age-dependent effect
of DHEA and DHEAS on chromaffin cell proliferation induced
by major adrenal growth factors, including EGF and LIF.
Results
Bovine Chromaffin Cells Are Able to Grow in Vitro. The capacity of
bovine chromaffin cells in primary culture to proliferate in vitro
has been evaluated by incorporation of BrdU. Chromaffin cells
isolated from young and adult animals (Fig. 2 A and B, respec-
tively) were both able to incorporate BrdU. To discriminate
labeled and unlabeled chromaffin cells from other cell types, a
double-labeling of the cells was performed with an antibody
directed against phenylethanolamine N-methyltransferase
(PNMT). In the presence of serum, bovine chromaffin cells were
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able to incorporate BrdU in vitro. No labeling was observed when
BrdU and PNMT antisera were replaced by PBS (Fig. 2C).
Effect of LIF and EGF on the Proliferation of Chromaffin Cells Is
Age-Dependent. To investigate the effects of LIF and EGF on cell
proliferation, we first evaluated proliferative activity with a
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Graded concen-
trations of LIF (2–200 ngml1) significantly increased the
proliferation of chromaffin cells from young animals incubated
for 4 days in serum-free medium, whereas EGF (2–200 ngml1)
had no effect (Fig. 3A). On the contrary, in the same range of
concentrations, EGF significantly increased the cell prolifera-
tion of cells from adult animals in primary culture, whereas LIF
was inactive (Fig. 3B).
Differential Action of DHEA and DHEAS on Induced Chromaffin Cell
Proliferation. In cells from young animals, as in cells from adult
animals, DHEA alone had no effect on bovine chromaffin cell
proliferation (data not shown), but decreased proliferation
induced by LIF and EGF, respectively, in a dose-dependent
manner (Fig. 4A and B). In the same way, dexamethasone (Dex),
which also exhibited no real effect on chromaffin cell prolifer-
ation, reduced proliferation induced by the growth factors in
both populations of cells (data not shown).
The sulfate ester of DHEA, DHEAS, did not induce any
modifications of the basal proliferation of young or adult chro-
maffin cells (data not shown). However, DHEAS did not affect
LIF-evoked chromaffin cell proliferation in young animals but
enhanced at high concentration (105 M) the EGF-induced
proliferation of chromaffin cell in adults (Fig. 4 C and D).
DHEA Has No Effect on Chromaffin Cell Death. The cytotoxic effect
of DHEA on chromaffin cells was evaluated by using a lactate
dehydrogenase release assay. We observed that LIF and EGF in
serum-free medium both decreased the cell death of chromaffin
cells from young and adult animals, respectively (Fig. 5). In
Fig. 1. Close contact of chromaffin cells with androgen-producing cortical
cells. (A) Section of bovine adrenal gland showing intermingling of cortical
cells and chromaffin cells (arrows). (B) Cryosection of human adrenal gland
showing zona reticularis adrenocortical cells immunostained (brown) with an
antibody against D-11 in close contact with the adrenomedullary cells (aster-
isks). (C) Electron micrograph of human adrenal gland exhibiting DHEA-
producing cells of the zona reticularis (ZR) in direct contact with chromaffin
cells of the medulla (Ch). Arrows indicate filopodia. V, vessel; SG, secretory
granule; Nuc, nucleus.
Fig. 2. Capacity of bovine chromaffin cells to grow in vitro. (A and B) Double
labeling for BrdU (brown nuclei) and PNMT (blue cytoplasm) of chromaffin
cells from juvenile (A) or adult (B) cattle incubated for 72 h in the presence of
10% FBS. (C) Control section incubated in the absence of primary antibodies.
(Scale bar, 50 m.)
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addition, DHEA at high concentrations (105 M) had no effect
alone on chromaffin cell death (data not shown). Furthermore,
DHEA did not induce any changes in the decrease of cell death
induced by growth factors in serum-free medium (Fig. 5).
Effect of DHEA and DHEAS on Chromaffin-Stimulated Proliferation
Was Not Affected by Steroid Receptor Antagonists. The inhibitory
effect of DHEA (10 M) on LIF/EGF-induced chromaffin cell
proliferation was not blocked either by androgen receptor
antagonist f lutamide (10 nM) or estrogen receptor antagonist
ICI 182,780 (10 nM) (Fig. 6). As expected, glucocorticoid
receptor antagonist RU 486 (1 M) completely abolished the
inhibitory effect of Dex (10 M) on growth factor-induced
chromaffin cells proliferation but had no effect on DHEA action
(data not shown). Flutamide, ICI 182,780, and RU had no effect
alone on cell proliferation.
In the same way, the stimulatory effect of DHEAS on EGF-
induced adult chromaffin cell proliferation was not modified by
both androgen and estrogen receptors antagonists (Fig. 7 A and
B) as well as GABAA receptor antagonist (Fig. 7C).
Discussion
DHEA- and DHEAS-producing cortical cells of the zona re-
ticularis and the chromaffin cells are tightly intermingled, sug-
gesting strong paracrine interactions. Our data suggest that
DHEA attenuates the effect of growth factors during life;
whereas, in adulthood, DHEAS acts as a local pro-survival agent
by increasing the effect of growth factors required for chromaffin
cell proliferation, such as EGF (Fig. 8).
Adrenal chromaffin cells and sympathetic neurons are derived
from a common sympathoadrenal precursor during embryogen-
esis. However, in contrast to sympathetic neurons, chromaffin
cells retain the ability to proliferate in response to a variety of
mitogens (22). Nevertheless, depending on the species studied,
there is a marked disparity in chromaffin cell proliferation in
vitro. Rat chromaffin cells proliferate in the presence of neuronal
growth factor (23), basic fibroblast growth factor (24), neuturin,
or glial cell line-derived neurotrophic factor (25), whereas mouse
chromaffin cells do not respond to any mitogens (26). Our data
show that, like rat chromaffin cells, young bovine and adult
bovine chromaffin cells are able to proliferate in vitro in the
presence of serum or in serum-free medium supplemented with
growth factors such as LIF or EGF.
As previously discussed, adrenomedullary cell proliferation is
regulated by various bioactive factors. In mice, the LIF receptor
is expressed during embryological development and in adult-
hood. LIF has been shown to be strongly involved in the PNMT
expression and in adrenal medulla innervation by sympathetic
neurons during embryogenesis (21). Our data strongly suggest
that LIF is also involved in adrenomedullary cell proliferation in
juvenile cattle but not in adult cattle. In contrast to LIF, EGF
does not induce any changes in young chromaffin cell prolifer-
ation in our model, but increases proliferation of cells from adult
animals. Juvenile and adult bovine adrenals medulla did not
present any difference at the histological level. In addition, no
changes were observed in the expression of classical chromaffin
cells markers, such as tyrosine hydroxylase, PNMT, synaptophy-
sin, or chromogranin A, by immunohistochemistry (data not
shown). The major difference between both tissues was the size:
juvenile adrenals are4 cm long, whereas adult adrenals usually
measured at least 5 cm. Adrenal medulla rapidly grows during
infancy and childhood and constitutes 1% of the whole gland
at birth and 9% in young adults. The growth then reduces in
adulthood and declines with senescence (27). These data suggest
a decrease in growth factors levels in the medulla and/or a
decrease in the chromaffin cell’s sensitivity to growth factors.
Fig. 3. Effects of LIF and EGF on the proliferation of chromaffin cells from
young (A) or adult (B) cattle. Cells were cultured for 96 h in DMEM/F12
containing the indicated growth factors. Cell proliferation was then assessed
with MTS reagent and measurement of absorbance at 490 nm. The results are
expressed as the mean  SEM of three to six independent experiments. ***,
P  0.001 vs. control.
Fig. 4. Effect of DHEA and DHEAS on chromaffin cell proliferation induced
by LIF in cells from young animals (AandC) or by EGF in cells from adult animals
(B andD). Cell proliferation was assessed with MTS reagent and measurement
of absorbance at 490 nm. The results are expressed as the mean SEM of three
to six independent experiments.
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Our results suggest a switch in the response of chromaffin cells
to growth factors with aging.
The proliferation of various tissues, such as vascular muscle
cells (28), endothelial cells (29), fibroblasts (30), T-lymphocytes (31), and preadipocytes (32), is influenced by DHEA. Becauseof the anatomical structure of the adrenal gland, steroid hor-
mones secreted by adrenal cortex have been suggested to interact
with chromaffin cell biology. In neuronal cell types, previous
studies have shown both the neuroprotective (7, 33–36) and
neurotoxic action of DHEA (37). However, these disparities in
the action of DHEA may reflect differences in cell models or
experimental paradigm. The present study has revealed that,
independently of age, DHEA decreases proliferation of sympa-
thoadrenal cells induced by LIF or EGF in young and adult
populations of cells, respectively. The antiproliferative action of
DHEA was not due to a cytotoxic effect of DHEA on bovine
chromaffin cells. In addition, some reports have shown opposite
Fig. 5. Effect of DHEA on chromaffin cell death. Cells were cultured for 96 h
in DMEM/F12 containing LIF in cells from young animal culture (A) or EGF in
cells from adult animals (B) in the absence (white bar) or presence (gray bar)
of DHEA at 105 M. The results are expressed as the mean  SEM of at least
three independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001 vs.
control.
Fig. 6. Effect of 105 M DHEA on 20 ng/ml LIF- and on 200 ng/ml EGF-induced
chromaffin cell proliferation after 96 h of pharmacological inhibition of
androgen receptor flutamide (A and C) and estrogen receptor ICI 182,780 (B
andD). Cell proliferation was assessed with MTS reagent and measurement of
absorbance at 490 nm. The results are expressed as the mean SEM of three
to seven independent experiments. ***, P  0.001 vs. control; ###, P  0.001
vs. response to LIF (A and B) or EGF (C and D).
Fig. 7. Effect of 105 M DHEAS on 200 ng/ml EGF-induced chromaffin cell
proliferation after 96 h of pharmacological inhibition of androgen receptor by
flutamide (A), estrogen receptor by ICI 182,780 (B), and GABAA receptor by SR
95531(C). Cell proliferation was assessed with MTS reagent and measurement
of absorbance at 490 nm. The results are expressed as the mean SEM of three
to eight independent experiments. ***, P 0.001 vs. control; #, P 0.05; ##,
P  0.01; ###, P  0.001 vs. response to EGF.
Fig. 8. Artistic rendition depicting potential interactions between adrenal
cortex and medulla during life. (Left) Young animals. (Right) Adult animals.
ZG, zona glomerulosa, ZF, zona fasciculata, ZR, zona reticularis.
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effects of DHEA and Dex, in particular in the regulation of
catecholamines secretion (38), in our model, DHEA and Dex
exhibited the same inhibitory activity on chromaffin cell-induced
proliferation. In contrast, DHEAS has been shown to display
various neuroprotective activities (6, 39, 40), and a different
action of DHEA and DHEAS on neuronal cell viability has been
suggested (37). Nevertheless, DHEA and DHEAS exhibit the
same protective effect against serum deprivation-induced apo-
ptosis in rat chromaffin cells (11). The results presented in the
present study show that DHEAS enhances proliferation of
bovine chromaffin cells from adult but not from young animals,
suggesting that DHEAS activity depends on age and/or growth
factors.
Levels of DHEA and DHEAS produced by the fetal adrenal
are very high in humans. After birth, there is a rapid decrease in
serum levels, and serum levels remain low until 6 years of age,
when levels start to rise again. DHEA sulfotransferase
(SULT2A1) is responsible for the sulfonation of DHEA to
DHEAS. This enzyme is highly expressed in fetal adrenal, in
particular in fetal and transitional zones. During childhood, an
increase in DHEAS production occurring before the puberty is
associated with accelerated expression of SULT2A1 in adrenal
reticularis (41). Changes in the expression of SULT2A1 and
consequently of DHEAS levels during development might be
important in the development of adrenal medulla.
The different actions of DHEA and DHEAS on chromaffin
cell proliferation appear to be independent of androgen and
estrogen receptors. Some effects of DHEAS in the brain are
mediated by the GABAA receptor (42), which is expressed by
bovine chromaffin cells (43). However, SR 95531, a GABAA
receptor antagonist, androgen, and estrogen receptor antago-
nists all failed to reverse the action of DHEA and DHEAS on
chromaffin cell proliferation. There is growing evidence for
DHEA/DHEAS action via specific receptors. Recently, a
DHEA-specific G protein-coupled receptor has been identified
in human and bovine endothelial cells. Nevertheless, this recep-
tor does not bind DHEAS (44). Furthermore, Gq/11 protein-
coupled membrane DHEAS binding sites, which are sensitive to
endocrine disrupting chemicals, have been identified on RBL-
2H3 rat mast cells (45). In addition, another DHEA-specific Gi
protein-coupled receptor has been found in PC12 cells and in
human chromaffin cells (46). However, these potential plasma
membrane receptors have not yet been isolated. Definitive
molecular and/or pharmacological studies have to be done
before we can draw any implication from one of these receptors
in its effects of DHEA/DHEAS in our model.
In conclusion, we have shown in this study that chromaffin
cells from young and adult cattle are able to grow in vitro. These
cells present age-dependent sensitivity to LIF and EGF. In
addition, DHEA and DHEAS are able to modulate in a differ-
ential manner the proliferation induced by these growth factors.
DHEA reduces the proliferation in both populations of cells,
whereas DHEAS exclusively increases the proliferation pro-
voked by EGF in adult cell culture. These effects are not
mediated through androgen or estrogen receptors. These data
support the view that adrenomedullary cells are under the
control of complex interactions between several factors released
by the adrenal cortex, such as growth factors and steroid
hormones. The aging process is associated with declines in the
levels of hormones and trophic factors, and the loss of adreno-
medullary functions with advancing age and tumor formation
could be due to an imbalance in the equilibrium of the paracrine
pro-/antiproliferative factors.
Materials and Methods
Cell Preparation and Culture. Bovine adrenal glands were obtained
from freshly slaughtered juvenile (1 year old) and adult (from 2
to 4 years old) male and female cattle. Juvenile adrenals are 4
cm long, and adult adrenals are usually 5 cm long. Adrenals
were trimmed free of adipose tissue and transported to the
laboratory in ice-cold PBS. The adrenals were put into 70%
ethanol for 10 s, and connective tissue was removed.
Primary cultures of bovine adrenochromaffin cells were ob-
tained after retrograde perfusion of bovine adrenal glands with
0.3% collagenase (Sigma–Aldrich, Munich, Germany) and 30
units/ml DNase I (Sigma–Aldrich), followed by dissociation of
the digested adrenal medulla. The cells were cultured in DMEM-
F12 (GIBCO, Paisley, U.K.) supplemented with 10% FBS
(GIBCO), 1% antibiotic-antimycotic solution (GIBCO), and 1%
gentamicin solution (GIBCO). Chromaffin cells were purified by
differential plating to remove adherent nonchromaffin cells as
described previously (47). They were plated at a density of 105
cells per milliliter in poly-L-lysine-coated 96-well plates (Becton
Dickinson, Bedford, MA). The cells were incubated in a humid-
ified atmosphere at 37°C (95% O2/5% CO2). After 24 h,
the medium was changed with the same medium to which 5%
FBS was added. Cultures were used 2–3 days after plating.
The serum-free medium that was used contained 107 M
ascorbic acid, 0.001% (wt/vol) transferrin, and 0.01% (wt/vol)
bacitracin.
Electron Microscopy. Adrenal glands were fixed in 2% formalde-
hyde and 2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.3.
Tissue slices were postfixed for 90 min (2% OsO4 in 0.1 M
cacodylate buffer, pH 7.3), dehydrated in ethanol, and embed-
ded in epoxy resin. Ultrathin sections were stained with uranyl
acetate and lead citrate and examined at 80 kV in a CM 10
electron microscope (Philips, Eindhoven, The Netherlands).
Immunohistochemistry. Adrenal tissue was fixed in 4% parafor-
maldehyde and processed as previously described (48). We
incubated 10-m sections overnight with mouse anti-D11 anti-
serum. For detection of primary antibodies, a horseradish per-
oxidase system was used (DAKO-Cytomation, Hamburg, Ger-
many), and the signal was visualized with 3,3-diaminobenzidine
(DAB tablet set; DAKO-Cytomation).
BrdU Staining.Chromaffin cells were plated at a density of 2 106
cells per milliliter on poly-L-lysine-coated glass coverslips and
incubated for 4 days in serum-containing medium with 10 M
BrdU (Sigma–Aldrich). The cells were washed twice with PBS at
room temperature and fixed with 4% paraformaldehyde in PBS
for 30 min. After three washes with PBS, DNA was denatured
by adding of 2 M HCL for 1 h at 37°C. Acid was then aspirated,
and coverslips were neutralized by three washes with 0.1 M
borate buffer (pH 8.5). The endogenous peroxidase was then
neutralized with 3% H2O2 for 15 min, and the sections were
blocked with 10% FBS diluted in PBS containing 1% BSA
(Sigma–Aldrich) and 0.3% Triton X-100 (Sigma–Aldrich). The
immunostaining procedure was performed with a mouse mono-
clonal anti-BrdU antibody diluted to 1:500 (Sigma–Aldrich) and
horseradish peroxidase-coupled goat anti-mouse diluted to
1:100 (DAKO-Cytomation). Color reactions were performed
with peroxidase substrate 3,3-diaminobenzidine. After three
washes, a second staining was performed with a sheep mono-
clonal anti-PNMT antibody diluted to 1:1500 (Chemicon, Te-
mecula, CA) and horseradish peroxidase-coupled rabbit anti-
sheep diluted to 1:100 (DAKO-Cytomation) using peroxidase
substrate 3,3,5,5 tetramethylbenzidine (TMB; Vector Labora-
tories, Burlingame, CA) as a chromogen. All antibodies were
diluted in PBS containing 1% BSA and 0.3% Triton X-100. To
study the specificity of the immunoreaction, primary antibodies
were substituted with PBS.
Measurement of Cell Proliferation. Chromaffin cells were stimu-
lated for 4 days in serum-free medium containing various
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concentrations of EGF (Sigma–Aldrich), LIF (Sigma–Aldrich),
and/or steroids. DHEA, Dex, and DHEAS (Sigma–Aldrich)
were initially diluted in ethanol (DHEA and Dex) or in DMSO
(DHEAS). The final concentration of ethanol/DMSO in each
well was 0.01%. After stimulation time, 20 l of MTS rea-
gent (Promega, Madison, WI) was added to each well (contain-
ing cells in 100 l of culture medium), and the plate was
incubated for 4 h at 37°C under a humidified atmosphere of 5%
CO2. The absorbance of each well was then measured at 492 nm
with a microplate reader (Mithras LB940; Berthold Techno-
logies, Bad Wildbad, Germany). Relative cell numbers were
quantified on the basis of the concentration of the formazan
product of MTS.
Evaluation of Cell Death. Chromaffin cells were stimulated for 4
days in serum-free medium containing various concentrations of
growth factors, cytokines, and/or DHEA. After stimulation time,
DHEA toxicity was evaluated by measuring lactate dehydroge-
nase (LDH) activity using the CytoTox96 nonradioactive assay
(Promega) and quantitated by measuring wavelength absor-
bance at 490 nm with a microplate reader (Mithras LB940;
Berthold Technologies). Cell death was assessed by the ratio of
LDH release in the medium to cytosolic LDH content.
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